T/CLPA 001-2022 Active Group standards

T/CLPA 001-2022 Antibody-based anti-cancer drug pharmacy service guideline

T/CLPA 001-2022 Antibody-based anti-cancer drug pharmacy service guideline

Publish Date: 1970-01-01 Implement Date: 1970-01-01 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us
Price: $ 140.00
Out of stock

Basic Information

Standard Code: T/CLPA 001-2022
Standard Type: Group standards
Standard Status: Active
is_force_gb: no
CCS Name: -
ICS Name: -
Publish Date: 1970-01-01
Implement Date: 1970-01-01

Scope

This document provides guidance on the full range of pharmaceutical services for antibody-based anti-tumor drugs currently listed in China (as of June 1, 2022). This document is applicable to medical institutions that provide pharmaceutical services for antibody-based anti-tumor drugs.

Development Information

Word Count: 180 Thousand words

Related Standards

Contact Us